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Abstract 1 
Purpose: To describe the distribution of corneal hysteresis (CH) in a large cohort and explore its 2 
associated factors and possible clinical applications.  3 
Design: Cross-sectional study within the UK Biobank, a large cohort study in the United Kingdom. 4 
Participants: We analyzed CH data from 93,345 eligible participants in the UK Biobank cohort, 5 
aged 40 to 69 years. 6 
Methods: All analyses were performed using left eye data. Linear regression models were used to 7 
evaluate associations between CH and demographic, lifestyle, ocular and systemic variables. 8 
Piecewise logistic regression models were used to explore the relationship between self-reported 9 
glaucoma and CH.  10 
Main outcome measures: CH (mmHg). 11 
Results: The mean CH was 10.6 mmHg (10.4 mmHg in males and 10.8 mmHg in females). After 12 
adjusting for covariables, CH was significantly negatively associated with male sex, age, Black 13 
ethnicity, self-reported glaucoma, diastolic blood pressure and height. CH was significantly 14 
positively associated with smoking, hyperopia, diabetes, systemic lupus erythematosus (SLE), 15 
greater deprivation (Townsend index) and Goldmann-correlated intraocular pressure (IOPg). Self-16 
reported glaucoma and CH were significantly associated when CH was less than 10.1mmHg (OR 17 
0.86, 95%CI 0.79-0.94 per mmHg CH increase) after adjusting for covariables. When CH exceeded 18 
10.1 mmHg, there was no significant association between CH and self-reported glaucoma.  19 
Conclusion: In our analyses, CH was significantly associated with factors including age, sex and 20 
ethnicity which should be taken into account when interpreting CH values. In our cohort, lower CH 21 
was significantly associated with a higher prevalence of self-reported glaucoma when CH was less 22 
than 10.1mmHg. CH may serve as a biomarker aiding glaucoma case detection.  23 
It is well recognized that variation in central corneal thickness (CCT) influences the accuracy of 24 
intraocular pressure (IOP) measurements1-3. It has also been hypothesized that CCT independently 25 
influences the risk of glaucoma, with thin CCT evidenced in those at highest risk4. However, this 26 
view is not universally accepted, as one particular high-risk group (African Americans) typically 27 
have thinner CCT than people of European heritage5. A plausible alternative explanation is that thin 28 
CCT is a biomarker for race, and identifies those at highest risk, attributable to other ocular or 29 
systemic factors. 30 
Corneal hysteresis (CH) offers an alternative index of corneal biomechanical characteristics to CCT 31 
and reflects the viscoelastic damping effect of corneal tissues, defined as the difference in air pulse 32 
pressure between inward and outward applanation forces6,7. Recent evidence indicates CH can also 33 
provide valuable information related to the presence, progression and response to therapy of 34 
glaucoma8,9. CH can be measured simultaneously with IOP using non-contact tonometry with 35 
augmented functionality. Differences in CH have been reported not only in glaucoma but also in 36 
many systemic diseases including thyroid eye disease10, rheumatoid arthritis11, psoriasis12, 37 
acromegaly13 and myotonic dystrophy14, which suggests CH may play a clinical role in fields other 38 
than ophthalmology. Previous studies on CH are limited by small sample sizes15,16. The distribution 39 
of CH and its associations with demographic, ocular and systemic variables remain to be accurately 40 
determined and confirmed in a large sample. 41 
The UK Biobank is one of the largest prospective population cohort studies in the world. In this 42 
study, we aimed to report the distribution of CH by age, sex and ethnicity, and explore its 43 
associations including the relationship between CH and self-reported glaucoma. We also tested the 44 
association between CH and 16 self-reported diseases selected based on existing literature10-13. 45 
Methods 46 
Study population 47 
The UK Biobank is a multisite community-based cohort study with 502,544 participants. All UK 48 
residents aged 40 to 69 who registered with the National Health Service and lived within 25 miles 49 
of any of the 22 assessment centers were invited to join the study. The initial visit assessments took 50 
place between 2006 and 2010. Eye assessments were carried out from 2009 in 6 recruitment centers 51 
(5 in England and 1 in Wales) which enrolled 133,953 participants. The UK Biobank study was 52 
approved by the North West Multi-centre Research Ethics Committee (Reference No. 06/MRE08/65) 53 
and adhered to the tenets of the Declaration of Helsinki. Written consent was obtained from every 54 
participant. More detailed information and protocols for UK Biobank are available online 55 
(http://www.ukbiobank.ac.uk/). 56 
Ethnicity was self-reported by participants and selected from White, Asian, Black, Chinese, mixed 57 
and other ethnic backgrounds. Socioeconomic status was derived using the Townsend deprivation 58 
index estimated using residence postcodes. This represents an indicative measure of economic 59 
deprivation in an area and higher scores indicate worse socioeconomic status17.  60 
Measurements 61 
Cohort characteristics and ophthalmic measures have been previous described18. Visual acuity was 62 
measured using a bespoke computerized logMAR acuity measure conforming to British Standard 63 
BS4274-196819, with left eye following right eye. Autorefraction was performed with the RC5000 64 
Auto Refkeratometer (Tomey, Japan). After measuring visual acuity and refraction, CH and 65 
Goldmann-correlated IOP (IOPg) were measured with the Reichert Ocular Response Analyser 66 
(ORA, Reichert, Inc. USA) according to a predetermined protocol (available online 67 
http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=100236). Participants who had any eye surgery 68 
within the preceding 4 weeks were excluded from tests. The measurements were performed first in 69 
the right eye and taken only once in each eye. If participants blinked during the test a further 70 
measurement was attempted.  71 
Blood pressure was measured with an automatic blood pressure monitor, HEM-70151T (Omron, 72 
The Netherlands). Two measurements were performed for each participant and the average was 73 
used for analysis if the values of both were available. Height was measured with the Seca 202 74 
instrument (Seca, UK). 75 
Medical History 76 
All diseases were self-reported by participants via verbal interviews conducted by trained nurses 77 
or via touchscreen questionnaires. Self-reported eye disorder(s) status was collected in the verbal 78 
interview or was selected by participants from a list of eye disorders in response to the question 79 
“Has a doctor told you that you have any of the following problems with your eyes?”. The list of 80 
eye disorders was: 81 
1. Diabetes related eye disease 82 
2. Glaucoma 83 
3. Injury or trauma resulting in loss of vision 84 
4. Cataract 85 
5. Macular degeneration 86 
6. Other serious eye condition 87 
7. None of the above 88 
8. Prefer not to answer 89 
9. Do not know 90 
Smoking and alcohol consumption were self-reported via touchscreen questionnaires. Smoking 91 
status was trichotomized for the purpose of analysis to current smokers, ex-smokers and those that 92 
have never smoked. Alcohol consumption was pentachotomized to daily/almost daily, weekly or 93 
more often, monthly or more often, occasional and never. The use of IOP lowering medications 94 
was recorded by trained interviewers. Only currently and regularly used ones were recorded. IOP 95 
lowering medication status was dichotomized to user and non-user for analysis. 96 
More detailed information about all variables is available online 97 
(http://biobank.ctsu.ox.ac.uk/crystal/index.cgi). 98 
Eligibility criteria 99 
All participants who had available ORA data (CH and IOPg) in the left eye were used for this 100 
analysis. Participants who met any exclusion criteria in Figure 1 were excluded from the analyses. 101 
0.5% of participants who were younger than 40 or older than 69 years were excluded based on the 102 
UK Biobank eligibility criteria. Extreme values (lowest 0.5% and highest 0.5%) of CH and IOPg 103 
may represent measurement errors and were therefore excluded. We excluded participants with a 104 
history of eye injury in their left eye, diabetes related eye disease, macular degeneration or other 105 
serious eye conditions (except for glaucoma and cataract) in either eye. Left eyes without data on 106 
ocular comorbidities and/or refractive error, and/or with high refractive errors (spherical 107 
equivalent >+5D or <-6D) and/or high astigmatism (absolute value of cylindrical power >3D) and/or 108 
a history of refractive surgery were excluded. Participants with a history of surgery or laser for 109 
glaucoma or ocular hypertension were also excluded. Of the 93,345 left eyes remained in analysis, 110 
1,208 eyes with self-reported glaucoma were excluded for analyses of CH distribution.   111 
Statistical analysis 112 
All analyses were performed using left eye data which were captured after right eye data as specified 113 
in the study protocol. This may mean left eye data are less prone to artefact, such as blinking, in our 114 
cohort20. We included refractive error in analyses as the spherical equivalent in dioptres (D, sphere 115 
power+1/2 cylinder power). For glaucoma status, controls were defined as participants without self-116 
reported glaucoma in either eye. 117 
A descriptive analysis of CH in left eyes stratified by age, sex and ethnicity was conducted after 118 
excluding all participants with self-reported glaucoma. One-way analysis of variance was performed 119 
to compare means of CH by age, sex and ethnicity.  120 
Associations between CH and other demographic, ocular and systemic factors and self-reported 121 
glaucoma were evaluated with univariable linear regression and all factors with p<0.05 in 122 
univariable analysis were also analyzed with multivariable linear regression.  123 
We analyzed the relationship between self-reported glaucoma and CH using the following steps: 124 
1) Locally weighted scatterplot smoothing (LOWESS)21, a method usually used to visualize 125 
the structure of data22, was used to explore the relationship between self-reported glaucoma 126 
and corneal hysteresis. The turning point(s) found on the LOWESS curve was used as 127 
node(s) for piecewise analysis.  128 
2) Piecewise logistic regression for self-reported glaucoma and CH was performed in three 129 
models after adjusting for covariables.  130 
3) The joint distribution of the proportion of self-reported glaucoma, CH and IOPg was 131 
displayed using a 3D bar chart.  132 
We then applied linear regression to evaluate the relationships between CH and 16 systemic diseases 133 
after adjusting for covariables. 134 
The 3D bar chart was plotted using Excel for Office 365 (MicrosoftCorp, CA, USA). All other 135 
analyses were performed and plots generated using STATA/SE-15 (StataCorp LLC, TX, USA).  136 
Results 137 
All analyses were performed using left eye data in this study. 111,942 UK Biobank participants had 138 
available CH values for left eyes. After data cleaning as shown in Figure 1, the mean CH was 10.60139 
±1.88 mmHg (95% CI 10.59-10.62 mmHg) in the 92,137 eyes without self-reported glaucoma. 140 
The distribution of mean CH stratified by age, sex and ethnicity is summarized in Table 1. A 141 
significant difference in CH was found between participants with different ethnicities (p<0.001). 142 
CH values were lower in Black people (9.62±1.87 mmHg, 95% CI 9.56-9.69 mmHg) compared to 143 
White participants (10.66±1.87 mmHg, 95% CI 10.65-10.67 mmHg). CH was significantly greater 144 
in females (10.79±1.86 mmHg, 95% CI 10.77-10.80 mmHg) compared to males (10.39±1.88 145 
mmHg, 95% CI 10.37-10.40 mmHg, p<0.001). Overall, CH was also significantly higher in younger 146 
people across the whole age spectrum enrolled (mean 10.91±1.91mmHg, 95% CI 10.87-147 
10.95mmHg for those aged 40-44 compared to 10.30±1.84mmHg, 95% CI 10.27-10.32mmHg for 148 
those aged 65-69, p<0.001).  149 
The associations of CH were analyzed with linear regression models as shown in Table 2. CH was 150 
significantly associated with all included factors except for visual acuity and alcohol intake 151 
frequency. In the multivariable linear regression model after adjusting for covariates, CH was 152 
significantly higher in women (0.193 mmHg, p=2.07×10-27), smokers (reference: never smoked; 153 
0.095 mmHg former smokers, p=7.71×10-13; 0.419 mmHg current smokers, p=1.22×10-84), 154 
participants with a higher Townsend deprivation index (0.012 mmHg/Unit, p=7.82×10-8) and self-155 
reported diabetes (0.283 mmHg, p=1.25×10-20). CH was significantly lower in older participants 156 
(-0.033 mmHg/year, p=0), Black participants (reference: white; -1.219 mmHg, p=1.03×10-260), 157 
Asian participants (reference: white; -0.461 mmHg, p=2.08×10-45), participants with higher blood 158 
pressure (-0.0076 mmHg/1mmHg diastolic blood pressure, p=1.29×10-33), greater height (-0.016 159 
mmHg/cm, p=4.71×10-61), greater myopia (0.034 mmHg/D, p=3.06×10-26) and in those with self-160 
reported glaucoma (-0.516 mmHg, p=1.13×10-15). 161 
Figure 2, Table 3 and Figure 3 show the relationship between self-reported glaucoma and CH. 162 
Overall, lower CH was associated with a higher proportion of self-reported glaucoma. As shown in 163 
Figure 2A, when CH was less than approximately 10mmHg, the proportion of self-reported 164 
glaucoma increased markedly when CH decreased. However, with increases in CH above 10mmHg 165 
the proportion of self-reported glaucoma remained relatively stable at around 1%. The LOWESS 166 
curve shapes were similar in analyses stratified by age (Figure 2B) and IOPg (Figure 2C), with sharp 167 
rises in the proportions of self-reported glaucoma at CH values less than approximately 10mmHg.  168 
Piecewise logistic regressions were performed with a node set at 10.1mmHg (Table 3). As shown in 169 
the online supplementary material, 10.1 mmHg was the smallest node that self-reported glaucoma 170 
and CH were significantly associated when CH was less than the node while there was no 171 
association between self-reported glaucoma and CH when CH was greater than the 10.1 mmHg 172 
node in all three models. When CH was less than 10.1 mmHg, higher CH was a protective factor 173 
for self-reported glaucoma. A 1 mmHg increase in CH was associated with an OR of 0.78 (95% CI 174 
0.73-0.82, p<0.001) after adjusting for age, sex and ethnicity in Model I, an OR of 0.82 (95% CI 175 
0.78-0.87, p<0.001) in Model II (Model I with further adjusting for IOPg) and an OR of 0.86 (95% 176 
CI 0.79-0.94, p<0.001) in Model III (the maximally adjusted model). When CH exceeded 10.1 177 
mmHg it was not associated with self-reported glaucoma in all three models (Table 3).  178 
The relationship between self-reported glaucoma, CH and IOPg is displayed using a 3D bar chart 179 
(Figure 3). In keeping with the analyses reported in Figure 2C and Table 3, the proportion of self-180 
reported glaucoma was highest in participants with high IOPg and low CH, and lowest in the 181 
participants whose IOPg was not high and CH was not low.   182 
We analyzed associations between CH and 16 self-reported disorders of the thyroid gland, pituitary 183 
gland and other immunological/systemic disorders (Table 4). Only systemic lupus erythematosus 184 
(SLE) was significantly associated with CH following correction for multiple testing (p<0.003125, 185 
Bonferroni-corrected threshold). CH was significantly higher in participants with self-reported 186 
SLE (0.549, 95% CI 0.237-0.862 mmHg in the fully adjusted model).  187 
Discussion 188 
In this large UK cohort, we have described mean CH stratified by age, sex and ethnicity (Table 1). 189 
We found that CH was significantly lower in Black participants and in older age groups, which is 190 
consistent with previously published findings15,23. Past studies indicate that CH and CCT are 191 
positively associated24-26 and CCT is negatively associated with darker skin pigmentation27. One 192 
explanation for the variation in CH by ethnicity may be differences mediated by changes in CCT. 193 
Conversely, previous publications revealed no significant association between CCT and age7,28,29, 194 
suggesting an independent association between lower CH and older age. 195 
CH was significantly higher in smokers in our cohort (both current and former smokers). A previous, 196 
smaller study had suggested this but results were inconclusive30. The mechanisms underlying the 197 
relationship between smoking and corneal changes are unknown31,32 and the association between 198 
smoking and corneal ectatic disorders is controversial33,34. An epidemiological study showed a 199 
marked reduction in the incidence of keratoconus amongst smokers34, implying altered corneal 200 
biomechanics. This is supported by experimental evidence of collagen crosslinking by 201 
formaldehyde, a constituent of cigarette smoke, with resulting increased resistance to collagenases34. 202 
Smoking has also been reported to damage the tear film35,36 and possibly the corneal endothelium37, 203 
which may influence CCT and CH measurements. We found no significant association between 204 
alcohol consumption and CH. 205 
Our findings in Figure 2, Table 3 and Figure 3 suggest that CH may be useful in glaucoma risk 206 
stratification in clinical practice. Figure 2 and Table 3 indicate that a CH value of 10.1 mmHg could 207 
play a role as cutoff point in clinical practice to evaluate a patient’s risk of glaucoma. When CH is 208 
less than 10.1mmHg, lower CH may be associated with a higher risk of glaucoma (OR 1.16, 95% 209 
CI 1.07-1.26 per mmHg CH decrease in the fully adjusted model). When CH was greater than 210 
10.1mmHg, the rate of self-reported glaucoma remained relatively stable with further increases in 211 
CH. Medeiros et al reported that lower CH with values below 10mmHg was a risk factor for 212 
glaucoma progression38. 213 
CH measurement demonstrates good repeatability39 and there are no significant diurnal fluctuations 214 
26,40, making CH measurement a potentially attractive addition to current glaucoma risk stratification 215 
methods. CH has been shown to be lower in different types of glaucoma including open angle 216 
glaucoma, angle closure glaucoma, normal tension glaucoma, pseudoexfoliative glaucoma and 217 
congenital glaucoma41-46. Lower CH is also positively associated with visual field progression8,38. 218 
Some studies have found a positive association between CH and glaucoma-related changes in optic 219 
disc morphology47-49 whereas others found no such relationship50-52. Unlike CH, IOP and CCT 220 
measurements are limited by significant diurnal variation26,40,53-55. Figure 2C, Table 3 and Figure 3 221 
show that CH and IOPg could be analyzed together in clinical settings to evaluate glaucoma risk, as 222 
the risk of self-reported glaucoma was highest in participants with low CH and high IOPg, and 223 
lowest in participants whose IOPg was not high and CH was not low.  224 
In analyses for associations between CH and self-reported disorders shown in Table 4, only SLE 225 
was significantly associated with CH at p<0.003 (Bonferroni-corrected threshold for multiple 226 
testing). We found that CH was significantly higher in participants with SLE, which is contradictory 227 
to the result in a case-control study which reported CH was lower in SLE patients56. Lower CH has 228 
also been reported in thyroid eye disease10, however we did not find an association between CH and 229 
thyroid disorders. We also did not find associations between CH and rheumatoid arthritis or psoriasis 230 
as previously published11,12. Participants with acromegaly in our cohort had higher CH values (at 231 
p<0.05), in agreement with findings from Ozkok and colleagues13, however our result was not 232 
significant after correction for multiple testing. Our study also shows higher CH amongst patients 233 
with diabetes as previously reported57,58. Former studies have yielded variable results when 234 
evaluating CH in diabetes58-61.  235 
The very large sample size and standardized techniques are major strengths of our study, allowing 236 
us to detect and quantify small effects. However, the study is limited by the fact that all disease 237 
statuses were self-reported by participants which can result in misclassification error62.  UK Biobank 238 
has a low response rate of 5.5% which limits external validity. With respect to glaucoma, there will 239 
be an under-ascertainment of disease since approximately 50% of cases may not have been 240 
diagnosed62. Meanwhile participants with ocular hypertension, suspected glaucoma or cataracts may 241 
report a diagnosis of glaucoma. The potential impact of these errors is unknown. We excluded 242 
participants with a past history of surgery or laser for glaucoma or ocular hypertension. A potential 243 
confounding variable in the reported association between CH and glaucoma is the use of IOP 244 
lowering medications, which may significantly alter corneal biomechanical properties9,63,64. The 245 
binary variable of current, regular IOP lowering medication use versus no use in this study may 246 
oversimplify the effects of different medications on corneal biomechanics. CH and IOPg in this 247 
study were measured together using the same instrument and adjusting one for the other makes 248 
interpretation difficult. Despite this, we found weak correlation between them (ρ=0.045) in the 249 
sample after data cleaning. Investigation into the association between CH and diseases including 250 
glaucoma, SLE and diabetes is scarce and we anticipate that future research will build on our 251 
findings.  252 
Our study offers CH reference values for future research and clinical practice. We also report 253 
associations between CH and age, sex, ethnicity, smoking status, refractive error, self-reported 254 
glaucoma, diabetes and SLE, which may be important when interpreting CH. CH measurement may 255 
play a role in clinical practice for glaucoma and other ocular and systemic conditions. 256 
 257 
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